2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2128

A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer
Abstract Number: 157

A Systematic Review of the Upper Limb Soft Tissue Comorbidities in Patients with Type 2 Diabetes Mellitus
Abstract Number: 1860

A Trial Testing Strategies to Enhance Patient Understanding of Drug Information: Experience Recruiting Subjects through an Online Patient Community
Abstract Number: 2169

A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study
Abstract Number: 1892

A20 Haploinsufficiency: Clinical Phenotypes and Disease Course of Patients with This Newly Recognized Autoinflammatory Disease
Abstract Number: 1932

A2A Adenosine Receptor (A2AR) Stimulation Modulates NR4A2 Orphan Receptor Expression during Osteoclast Differentiation
Abstract Number: 59

Abaloparatide, a Novel PTHrP Analog, Increased Bone Mass and Density at Cortical and Trabecular Sites in an Orchiectomized Rat Model of Male Osteoporosis
Abstract Number: 1937

Abaloparatide, an Osteoanabolic PTHrP Analog, Increased Bone Mineral Density in Rabbits with Glucocorticoid Induced Osteopenia
Abstract Number: 419

Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience
Abstract Number: 1468

Abatacept Retention Rates, Overall and By Participating Country, and Prognostic Factors of Retention in Patients with RA: 2-Year Results from a Real-World Observational Study
Abstract Number: 1817

Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Abstract Number: 1073

Aberrant Cell Signaling in Peripheral Blood Mononuclear Cells upon Interferon Alpha Stimulation in Patients with Primary Sjögren’s Syndrome Associates with Type I Interferon Signature
Abstract Number: 2705

Aberrant Expression and Function of Human Circulating T Follicular Helper Cells and Its Subsets in IgG4 Related Disease
Abstract Number: 2421

Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis
Abstract Number: 1318

Abnormal Cerviovaginal Cytology in Adolescents with Systemic Lupus Erythematosus: A Retrospective Case Series

« Previous Page
1
…
6
7
8
9
10
…
201
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].